Trade

with

Anthera Pharmaceuticals Inc
(NASDAQ: ANTH)
AdChoices
1.98
+0.09
+4.49%
After Hours :
-
-
-

Open

1.93

Previous Close

1.90

Volume (Avg)

29.91k (189.33k)

Day's Range

1.92-1.99

52Wk Range

1.53-3.79

Market Cap.

43.04M

Dividend Rate ( Yield )

-

Beta

1.54

Shares Outstanding

22.71M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
  • Management effectiveness
Industry Drug Manufacturers – Major
Highlights
Analyst Recommendation: Not Available
    • Revenue

    • 0

    • Net Income

    • -30.86M

    • Market Cap.

    • 43.04M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 1.54

    • Forward P/E

    • -

    • Price/Sales

    • -

    • Price/Book Value

    • 4.12

    • Price/Cash flow

    • -1.50

      • EBITDA

      • -27.91M

      • Return on Capital %

      • -81.24

      • Return on Equity %

      • -158.57

      • Return on Assets %

      • -81.24

      • Book Value/Share

      • 0.46

      • Shares Outstanding

      • 22.71M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      -
      Not Available
        • 1 Year Price Target

        • 24.00

        • Credit Rating

        • -

        • Analysts

        • 0

        • EPS Estimate

        • -2.00

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 0.00

          • 0.89

          • Net Income

            YTD/YTD (last year)

          • -

          • 7.80

          • Net Income

            Q/Q (last year)

          • -

          • 4.50

          • Sales (Revenue)

            5-Year Annual Average

          • 0.00

          • 6.10

          • Net Income

            5-Year Annual Average

          • -

          • 3.73

          • Dividends

            5-Year Annual Average

          • -

          • 2.17

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • -

            • 69.92

            • Pre-Tax Margin

            • -

            • 21.84

            • Net Profit Margin

            • -

            • 18.37

            • Average Gross Margin

              5-Year Annual Average

            • -

            • 71.90

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 21.92

            • Average Net Profit Margin

              5-Year Annual Average

            • -

            • 903.40B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • 0.54

              • 0.32

              • Current Ratio

              • 2.68

              • 1.92

              • Quick Ratio

              • 2.62

              • 1.31

              • Interest Coverage

              • -24.31

              • 17.64

              • Leverage Ratio

              • 2.30

              • 2.03

              • Book Value/Share

              • 0.46

              • 14.62

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -1.26

                • 22.62

                • P/E Ratio 5-Year High

                • -48.20

                • 193.96

                • P/E Ratio 5-Year Low

                • -1.02

                • 87.26

                • Price/Sales Ratio

                • -

                • 3.79

                • Price/Book Value

                • 4.12

                • 3.78

                • Price/Cash Flow Ratio

                • -1.50

                • 14.31

                • Key Metrics

                • Company

                  • Shares Short

                    as of -

                  • -

                  • Short Ratio

                    as of -

                  • -

                  • Short % of Float

                    as of -

                  • -

                  • Shares Short

                    prior month

                  • -

                  • Trailing Annual Dividend Yield

                  • -

                  • 5 Year Average Dividend Yield

                  • -

                  • Key Metrics

                  • Company

                    • Payout Ratio

                    • -

                    • Dividend Date

                    • -

                    • Ex-Dividend Date

                    • -

                    • Last Split Factor

                      new per old

                    • -

                    • Last Split Date

                    • -

                    • Key Metrics

                    • Company

                    • Industry

                      • Return on Equity %

                        (5-Year Average)

                      • -158.57

                        (-)

                      • 17.42

                        (18.66)

                      • Return on Assets %

                        (5-Year Average)

                      • -81.24

                        (-130.20)

                      • 8.45

                        (8.77)

                      • Return on Capital %

                        (5-Year Average)

                      • -88.21

                        (-)

                      • 12.41

                        (13.18)

                      • Income/Employee

                      • -

                      • 90.07k

                      • Inventory Turnover

                      • -

                      • 2.46

                      • Asset Turnover

                      • -

                      • 0.46

                      Current Historical
                      Financials
                      • Income Statement
                      • Balance Sheet
                      • Cash Flow
                      Operating Income
                      -28.25M
                      Operating Margin
                      -
                      Total Equity
                      -
                      Retained Earnings
                      -
                      Free Cashflow
                      -
                      Price/Cashflow
                      -1.50
                      Ownership

                      Institutional Ownership

                      54.74%

                      Top 10 Institutions

                      42.92%

                      Mutual Fund Ownership

                      9.84%

                      Float

                      96.47%

                      5% / Insider Ownership

                      3.30%

                      Corporate insiders or major stockholders reporting trading activity in the stock.

                      Top Mutual Fund Owners

                      Top Institutional Owners

                      Mutual Fund Name

                      Institution Name

                      • Mutual Fund Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Franklin Biotechnology Discovery

                      •  

                        671,850

                      • 29.51

                      • 3.28

                      • Rhenman Healthcare Eq L/S

                      •  

                        300,000

                      • 42.86

                      • 1.32

                      • Franklin Biotechnology Discovery Fund

                      •  

                        292,062

                      • 0.00

                      • 1.29

                      • Vanguard Total Stock Mkt Idx

                      •  

                        283,343

                      • 0.00

                      • 1.25

                      • Vanguard Extended Market Index Fund

                      •  

                        135,113

                      • 3.22

                      • 0.59

                      • FCP OP MEDICAL BioHealthTrends

                      •  

                        133,932

                      • 0.00

                      • 0.58

                      • Vanguard Instl Total Stock Market Index

                      •  

                        110,168

                      • 0.00

                      • 0.49

                      • Fidelity Spartan® Extended Mkt Indx Fd

                      •  

                        86,499

                      • 0.00

                      • 0.38

                      • APO Medical Opportunities

                      •  

                        64,182

                      • 0.00

                      • 0.27

                      • RHO Investments SIL

                      •  

                        36,984

                      • -0.08

                      • 0.19

                      • Institution Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Deerfield Management Co

                      •  

                        1,691,857

                      • 0.00%

                      • 7.47

                      • Great Point Partners LLC

                      •  

                        1,500,000

                      • +9.55%

                      • 6.62

                      • Franklin Advisers, Inc.

                      •  

                        963,912

                      • +18.88%

                      • 4.26

                      • Orbimed Advisors, LLC

                      •  

                        851,750

                      • -8.68%

                      • 3.76

                      • Bvf Inc

                      •  

                        559,624

                      • 0.00%

                      • 2.47

                      • Perceptive Advisors LLC

                      •  

                        478,456

                      • 0.00%

                      • 2.11

                      • Vanguard Group, Inc.

                      •  

                        470,946

                      • +10.02%

                      • 2.08

                      • Sabby Management LLC

                      •  

                        448,000

                      • -34.89%

                      • 1.98

                      Company Profile

                      Sector

                      Healthcare

                      Industry

                      Drug Manufacturers – Major

                      Type

                      Distressed

                      Style

                      Small Growth

                      Anthera Pharmaceuticals, Inc., was incorporated on September 9, 2004 in the state of Delaware. It is a biopharmaceutical company focused on developing and commercializing therapeutics to treat serious diseases associated with inflamm...moreation and autoimmune diseases. The Company’s product candidate, blisibimod, targets elevated levels of B-cell activating factor, or BAFF, which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus, or lupus, IgA nephropathy, lupus nephritis, multiple myeloma, vasculitis, idiopathic thrombocytopenia purpura, and others. BAFF, also known as BLyS, is a tumor necrosis family member and is critical to the development, maintenance and survival of multiple B-cell lineages as well as plasma cells. Its product developme...morent program is focused on development of blisibimod for use as a therapeutic treatment for lupus and other serious autoimmune diseases for which it believes current treatments are either inadequate or non-existent. It currently relies on contract manufacturers to produce drug substances and drug products required for its clinical studies under current Good Manufacturing Practice with oversight by its internal managers. The Company competes with pharmaceutical and more established biotechnology companies, specialty pharmaceutical and generic drug companies, academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization. The Company is subject to federal, state and local laws governing the use, handling and disposal of these materials.lessless

                      Key People

                      Paul F. Truex

                      CEO/Director/President

                      Dr. Christopher S. Henney, PhD

                      Chairman of the Board/Director

                      Steven B. Engle

                      Director

                      Mr. Brian R. Mueller

                      Director

                      Dr. Philip T. Sager, M.D.

                      Director

                      • Anthera Pharmaceuticals Inc

                      • 25801 Industrial Boulevard

                      • Hayward, CA 94545

                      • USA.Map

                      • Phone: +1 510 856-5600

                      • Fax: +1 510 856-5597

                      • anthera.com

                      Incorporated

                      2004

                      Employees

                      25

                      Send Feedback

                      We appreciate your input!

                      • I'm having trouble signing into my Microsoft account

                      • I’m having problems with the services stripe (Mail, Facebook, etc.)

                      • There is an issue with my weather information

                      • I see an error in the content

                      • Other

                      Please give an overall site rating: